icon-close
fren

Also in this section

Stem Cell Network welcomes over 500 delegates to Montréal for the 2024 Till & McCulloch Meetings

Montréal, QC – November 4, 2024 – The Stem Cell Network (SCN) is excited to welcome over 500 researchers, clinicians, and industry experts to Montréal for the 2024 Till & McCulloch Meetings (TMM), Canada’s premier stem cell and regenerative medicine conference. Taking place from November 4 to 6, this annual conference will highlight groundbreaking research, foster collaboration, and spotlight innovative advances in the field of regenerative medicine.

“We are thrilled to host TMM2024 in Montréal this year,” said Dr. Michael Rudnicki, Scientific Director of the Stem Cell Network. “This year’s program reflects the rapid advancements being made in stem cell and regenerative medicine research, and it’s inspiring to see world-leading researchers, trainees, and entrepreneurs come together to discuss the latest research and consider how the field is advancing.”

The conference will feature an impressive line-up of speakers, including two keynote speakers:

  • Dr. Deepak Srivastava, from the Gladstone Institutes & the University of California, San Francisco Medical Center, will open the conference sharing insights on the topic of cellular reprogramming approaches in human disease
  • Dr. Pieter Cullis, from the University of British Columbia, will close the conference, reflecting on his research in the design of lipid nanoparticles to enable gene therapies.

Always a conference highlight, this year’s Till & McCulloch Lecture will be presented by Dr. Slava Epelman, from the University Health Network, in recognition of his contribution to global stem cell research through his paper published in Nature Cardiovascular Research entitled, “Primitive macrophages induce sarcomeric maturation and functional enhancement of developing human cardiac microtissues via efferocytic pathways.” In addition, Dr. Shenghui Liang, from the University of British Columbia, will be presented with the prestigious Drew Lyall Award of Excellence, recognizing the top-ranked abstract in the TMM2024 abstract competition.

“TMM is also the perfect opportunity to meet with trainees, who are the future leaders of our field,” added Dr. Rudnicki. “I look forward to taking in the over 240 poster presentations as well as their oral presentations this year.”

Two trainees are also being recognized with awards at TMM2024. Congratulations to:

This year TMM delegates will also have the opportunity to participate in popular sessions such as the Meet the Experts Luncheon; lunchtime breakouts, including one led by Dr. Imogen Coe, from Toronto Metropolitan University, discussing strategies to enhance equity, diversity and inclusion in research programs; and a new series of specialized workshops on Wednesday afternoon focused on topics such as commercializing regenerative medicine in Canada, patient engagement, and science policy and advocacy.  

“This year’s TMM is set to be one of the best yet,” said Dr. Rudnicki. “We could not host this conference without the numerous volunteers, committees, and sponsors who help make TMM possible each and every year. A very big thank you to all of you.”

For more information on the 2024 Till & McCulloch Meetings, visit www.tillandmcculloch.ca.

-30-

About the Till & McCulloch Meetings
The Till & McCulloch Meetings (TMM) is Canada’s premier stem cell research and regenerative medicine conference, attracting attendees from across the country and internationally since 2012. Hosted by the Stem Cell Network, the conference brings together world-class scientists, post-graduate students, industry experts and legal and policy scholars who will share the latest research advances and techniques in the field. To register or learn more about the conference visit www.tillandmcculloch.ca.

About the Stem Cell Network
The Stem Cell Network (SCN) is a Canadian not-for-profit that supports stem cell and regenerative medicine research; training the next generation of highly qualified personnel; and knowledge mobilization and transfer of stem cell and regenerative medicine research. From the lab to the clinic, SCN’s goal is to power life-saving therapies and technologies through regenerative medicine research for the benefit of all. Created in 2001, with support from the Government of Canada, the Network has grown from a few dozen labs to more than 270 world-class research groups, supporting over 250 research projects and 30 clinical trials. Since its inception, over 25 biotech companies have been catalyzed or enhanced and more than 7,000 highly qualified personnel have been trained. In 2023, the Government of Canada announced additional funding for SCN through the Strategic Science Fund that will support SCN activities and research through to the end of the decade.